Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/38—Nitrogen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/18—Feminine contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
  • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/38—Nitrogen atoms
  • C07D215/42—Nitrogen atoms attached in position 4
  • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the invention relates to a compound having FSH receptor modulatory activity, in particular a tetrahydroquinoline derivative, to a pharmaceutical composition containing the same, as well as the use of said compound in medical therapy.
• Gonadotropins serve important functions in a variety of bodily functions including metabolism, temperature regulation and the reproductive process. Gonadotropins act on specific gonadal cell types to initiate ovarian and testicular differentiation and steroidogenesis.
• the hypophyseal gonadotropin FSH (follicle stimulating hormone) for example plays a pivotal role in the stimulation of follicle development and maturation whereas LH (luteinizing hormone) induces ovulation (Sharp, R.M. Clin Endocrinol. 33:787-807, 1990; Dorrington and Armstrong, Recent Prog. Horm. Res. 35:301- 342,1979).
• FSH follicle stimulating hormone
• LH luteinizing hormone
• the gonadotropin FSH is released from the anterior pituitary under the influence of gonadotropin-releasing hormone and oestrogens, and from the placenta during pregnancy.
• FSH acts on the ovaries promoting development of follicles and is the major hormone regulating secretion of oestrogens.
• FSH is responsible for the integrity of the seminiferous tubules and acts on Sertoli cells to support gametogenesis.
• Purified FSH is used clinically to treat infertility in females and for some types of failure of spermatogenesis in males.
• Gonadotropins destined for therapeutic purposes can be isolated from human urine sources and are of low purity
• FSH human FSH
• Recombinant human FSH is available commercially and is being used in assisted reproduction (Olijve et al. Mol. Hum. Reprod. 2:371, 1996; Devroey et al. Lancet 339:1170, 1992).
• the actions of the FSH hormone are mediated by a specific plasma membrane receptor that is a member of the large family of G-protein coupled receptors. These receptors consist of a single polypeptide with seven transmembrane domains and are able to interact with the Gs protein, leading e.g. to the activation of adenylate cyclase.
• the FSH receptor is a highly specific target in the ovarian follicle growth process and is exclusively expressed in the ovary. Blocking this receptor or inhibiting the signaling which is normally induced after FSH-mediated receptor activation will disturb follicle development and thus ovulation and fertility. Low molecular weight FSH antagonists could therefore form the basis for new contraceptives. Such FSH antagonists could give rise to diminished follicle development (no ovulation) with still sufficient estrogen production left to avoid adverse effects on e.g. bone mass. On the other hand, compounds that stimulate FSH receptor activity may serve to mimic the gonadotropic effect of the natural ligand.
• the present invention describes the preparation of low molecular weight hormone analogs that selectively have modulatory activity on the FSH receptor.
• the compounds of the invention can either be used as (partial) agonists or (partial) antagonists of the FSH-receptor.
• R 1 and R 2 are H or Me
• R 3 is H, hydroxy, (l-4C)alkoxy, (di)(l-4C)alkylamino(2-4C)alkoxy or (2- 6)heterocycloalkyl(2-4C)alkoxy;
• R 4 is H, OH, (l-4C)alkoxy or R 7;
• R 5 is H, OH, (l-4C)alkoxy or R 7; with the proviso that if R 4 is H, R 5 is not H, OH or (l-4C)alkoxy and that if R 5 is H, R 4 is not H, OH or (l-4C)alkoxy;
• R 6 is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, (2-6C)heterocycloalkyl or (1-
• R 7 is amino, (di)(l-4C)alkylamino, (6C)arylcarbonylamino, (6C)arylcarbonyloxy, (2-
• R 8 is hydroxy, amino, (l-4C)alkoxy, (di)(l-4C)alkylamino, (2-6C)heterocycloalkyl, (2-
• R 9 is aminocarbonyl, (di)(l-4C)alkylaminocarbonyl, (2-5C)heteroaryl or (6C)aryl.
• R 4 and R 5 can independently be selected form each of the groups mentioned and need not be the same.
• the compounds according to the present invention modulate the FSH receptor function and can be used for the same clinical purposes as native FSH if they behave like agonists, with the advantage that they display altered stability properties and may be administered differently. If they block the FSH receptor they can be used e.g. as a contraceptive agent.
• the FSH-receptor modulators of the present invention may be used for treating infertility, for contraception and for treatment of hormone-dependent disorders such as breast cancer, prostate cancer, and endometriosis.
• (l-4C)alkyl as used herein means a branched or unbranched alkyl group having 1-4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl.
• (l-6C)alkyl as used herein means a branched or unbranched alkyl group having 1-6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl and hexyl.
• (l-5C)Alkyl groups are preferred, (l-4C)alkyl being the most preferred.
• (3-8C)cycloalkyl means a cycloalkyl group having 3-8 carbon atoms, being cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. (3- 6C)cycloalkyl groups are preferred.
• (2-6C)heterocycloalkyl means a heterocycloalkyl group having 2-6 carbon atoms, preferably 3-5 carbon atoms, and at least including one heteroatom selected from N, O and/or S, which may be attached via a heteroatom if feasible, or a carbon atom.
• Preferred heteroatoms are N or O.
• Most preferred are piperidinyl, piperazinyl, morpholinyl and pyrrolidinyl.
• (l-4C)alkoxy means an alkoxy group having 1-4 carbon atoms, the alkyl moiety having the same meaning as previously defined.
• (l-2C)Alkoxy groups are preferred.
• (2-4C)alkoxy means an alkoxy group having 2-4 carbon atoms, the alkyl moiety having the same meaning as previously defined.
• (di)(l-4C)alkylamino as used herein means an amino group, monosubstituted or disubstituted with alkyl groups, each of which contain 1-4 carbon atoms and has the same meaning as previously defined.
• (6C)aryl as used herein means a phenyl group, which may optionally be substituted with one or more substituents selected from hydroxy, amino, iodo, bromo, chloro, fluoro, nitro, trifluoromethyl, cyano, phenyl, (l-4C)alkyl, (l-4C)alkoxy, (1- 4C)(di)alkylamino, the alkyl, alkoxy and (di)alkylamino moieties having the same meaning as previously defined, for example phenyl, 3,5-dibromophenyl, 4-biphenyl, 3,5-dichlorophenyl, 3-bromo-6-methylamino-phenyl, 3-chloro-2,6-dimethoxyphenyl and 3,5-dimethylphenyl.
• (2-5C)heteroaryl means a substituted or unsubstituted aromatic group having 2-5 carbon atoms, at least including one heteroatom selected from N, O and/or S, like imidazolyl, pyridyl, pyrimidyl, thienyl or furyl.
• the substituents on the heteroaryl group may be selected from the group of substituents listed for the (6C)aryl group.
• the heteroaryl group may be attached via a carbon atom or a heteroatom, if feasible.
• Preferred heteroaryl groups are thienyl, furyl and pyridyl.
• di(l-4C)alkylamino(2-4C)alkoxy as used herein means a (di)alkylamino group, the alkyl moeity or alkyl moieties of which each contains 1-4 carbon atoms, connected via the amino group to the alkyl moiety of an alkoxy group having 2-4 carbon atoms, in which the (di)alkylamino group and the alkoxy group have the same meaning as previously defined.
• (2-6C)heterocycloalkyl(2-4C)alkoxy as used herein means a heterocycloalkyl group having 2-6 carbon atoms, connected to the alkyl moiety of an alkoxy group having 2-4 carbon atoms, in which the alkoxy group and the heterocycloalkyl group have the same meaning as previously defined.
• (6C)arylcarbonylamino means a phenyl group, optionally substituted with one or more substituents selected from the group of substituents listed for the (6C)aryl group, connected to the carbonyl moiety of a carbonylamino group, the (6C)aryl moiety having the same meaning as previously defined.
• (6C)arylcarbonyloxy means a phenyl group, optionally substituted with one or more substituents selected from the group of substituents listed for the (6C)aryl group, connected to the carbonyl moiety of a carbonyloxy group, the (6C)aryl moiety having the same meaning as previously defined.
• (2-5C)heteroarylcarbonylamino as used herein means a heteroaryl group containing 2-5 carbon atoms, optionally substituted with one or more substituents selected from the group of substituents listed for the (6C)aryl group, connected to the carbonyl moiety of a carbonylamino group.
• the heteroaryl moiety in the heteroarylcarbonylamino group has the same meaning as previously defined.
• (2-5C)heteroarylcarbonyloxy as used herein means a heteroaryl group containing 2-5 carbon atoms, optionally substituted with one or more substituents selected from the group of substituents listed for the (6C)aryl group, connected to the carbonyl moiety of a carbonyloxy group.
• the heteroaryl moiety in the heteroarylcarbonyloxy group has the same meaning as previously defined.
• (2-6C)heterocycloalkylcarbonylamino as used herein means a heterocycloalkyl group having 2-6 carbon atoms, connected to the carbonyl moiety of a carbonylamino group, the heterocycloalkyl group having the same meaning as previously defined.
• (di)(l-4C)alkylaminocarbonyl as used herein means a (di)alkylaminogroup, the alkyl group(s) of which having 1-4 carbon atoms, connected via the amino group to a carbonyl group, the (di)alkylamino group having the same meaning as previously defined.
• (di)(l-4C)alkylaminocarbonylamino as used herein means a (di)alkylaminogroup, the alkyl group(s) of which having 1-4 carbon atoms, connected via the amino group to the carbonyl moiety of a carbonylamino group, thus providing a urea functionality, the (di)alkylamino group having the same meaning as previously defined.
• (l-4C)alkoxycarbonylamino as used herein means an alkoxy group having 1- 4 carbon atoms, attached to the carboyl moiety of a carbonylamino group, thus providing a carbamate functionality, the alkoxy group having the same meaning as previously defined
• R 8 -(2-4C)alkylamino as used herein means a R 8 group attached to the alkyl moiety of a (2-4C)alkylamino group, having the same meaning as previously defined.
• R 8 -(2-4C)alkoxy as used herein means a R 8 group attached to the alkyl moiety of a (2-4C) alkoxy group, having the same meaning as previously defined.
• R 9 -methylamino as used herein means a R 9 group attached to the methyl moiety of a methylamino group.
• R 9 -methoxy as used herein means a R 9 group attached to the methyl moiety of a methoxy group.
• pharmaceutically acceptable salt represents those salts which are, within the scope of medical judgement, suitable for use in contact for the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
• Pharmaceutically acceptable salts are well known in the art.
• a free base function may be obtained during the final isolation and purification of the compounds of the invention, or separately by reacting a free base function, if present, with a suitable mineral acid such as hydrochloric acid, phosphoric acid, or sulfuric acid, or with an organic acid such as for example ascorbic acid, citric acid, tartaric acid, lactic acid, maleic acid, malonic acid, fumaric acid, glycolic acid, succinic acid, propionic acid, acetic acid, methanesulfonic acid, and the like.
• an acid function can be reacted with an organic or a mineral base, like sodium hydroxide, potassium hydroxide or lithium hydroxide.
• the invention in another embodiment relates to compounds according to Formula I, wherein R 3 is H, hydroxy or (l-4C)alkoxy.
• the invention also relates to compounds of formula I, wherein R 4 is H, OH or (1- 4C)alkoxy.
• the invention provides compounds of Formula I wherein R 5 is OH, (l-4C)alkoxy or R 7 .
• R 6 is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl or (l-6C)alkyl.
• the invention relates to compounds according to Formula I wherein R 6 is (2-5C)heteroaryl or (6C)aryl.
• R 6 is (2-5C)heteroaryl or (6C)aryl.
• the heteroaryl group in R 6 consists of 4 or 5 C atoms.
• the invention also relates to compounds according to Formula I wherein R 7 is (di)(l- 4C)alkylamino, (2-5C)heteroarylcarbonylamino, (2-5C)heteroarylcarbonyloxy, R 8 -(2- 4C)alkoxy, R 9 -methylamino or R 9 -methoxy.
• R 7 is (di)(l-4C)alkylamino, (2-5C)heteroarylcarbonyloxy, R 8 -(2-4C)alkoxy, R 9 - methylamino or R 9 -methoxy.
• the invention relates to compounds according to Formula I wherein R 7 is (di)(l -4C)alkylamino, R 8 -(2-4C)alkoxy, R 9 -methylamino or R 9 -methoxy.
• the invention relates to compounds according to Formula I wherein R 8 -(2-4C)alkoxy in R 7 is R 8 -ethoxy.
• the invention relates to compounds according to Formula I wherein R 8 -(2-4C)alkylamino in R 7 is R 8 -ethylamino.
• the invention provides compounds of Formula I wherein R 8 is amino, (di)(l-4C)alkylamino, • (2-6C)heterocycloalkyl, (2- 6C)heterocycloalkylcarbonylamino or (1 -4C)alkoxycarbonylamino.
• the invention provides compounds of Formula I wherein R 8 is amino, (di)(l-4C)alkylamino, (2-6C)heterocycloalkyl or (l-4C)alkoxycarbonylamino.
• the invention provides compounds of Formula I wherein R 8 is amino, (di)(l-4C)alkylamino, (2-6C)heterocycloalkyl or (2- 6C)heterocycloalkylcarbonylamino.
• the invention also relates to compounds according to Formula I wherein R 8 is amino, ( ⁇ )(l-4C)alkylamino or (2-6C)heterocycloalkyl.
• R 8 in the compounds of Formula I is (di)(l- 4C)alkylamino or (2-6C)heterocycloalkyl.
• the invention relates to compounds according to Formula I wherein the heterocycloalkyl group in R 8 consists of 4 or 5 C atoms.
• R 9 according to Formula I is aminocarbonyl, (2-5C)heteroaryl or (6C)aryl
• the heteroaryl group in R 9 according to Formula I consists of 3, 4 or 5 C atoms.
• Yet another aspect of the invention concerns compounds wherein all specific definitions of the groups R 1 through R 9 as defined here above are combined in the compound of Formula I.
• l,2-dihydro-2,2,4- trimethylquinolines of formula Ill-a can be prepared by reacting the corresponding aniline of formula II with acetone in the presence of MgS0 4 , 4-tert-butylcatechol and iodine (L.G. Hamann, R.I. Higuchi, L. Zhi, J.P. Edwards and X.- ⁇ . Wang, J. Med. Chem, 41:623, 1998).
• the reaction can be performed in acetone using lanthanide trifiates (e.g. scandium triflate) as catalysts.
• lanthanide trifiates e.g. scandium triflate
• the reaction can be run at room temperature or at elevated temperatures using conventional heating or microwave irradiation (M. E. Theoclitou and L. A. Robinson, Tetrahedron Lett.43:3907, 2002).
• anilines of general structure II can be reacted with an appropriately substituted 1-methylstyrene derivative and formaldehyde in acetonitrile at ambient or elevated temperature to give compounds of general structure V-b.
• Related cyclizations are described in literature: J.M. Mellor and G.D. Merriman, Tetrahedron, 51:6115, 25 1995.
• Reduction of the nitro group of the compounds of general structure Vl-a-b can be accomplished by a large variety of methods well known in the art for the reduction of aromatic nitro compounds such as transition metal catalyzed hydrogenation, treatment with sulfides, treatment with iron or other metals and (mild) acid, treatment with tin dichloride under acidic conditions and the like. More specifically, the reduction of the nitro group of the compounds of general formula Vl-a-b can be accomplished by treatment with zinc dust and acetic acid in THF or 1,4-dioxane in the temperature range of0 °C to l00 °C.
• 6-N-acylation of compounds of formula Vll-a-b can be carried out using standard conditions, well known to those skilled in the art to give compounds of general structure I-a-b.
• compounds of formula VH are reacted in a solvent such as dichloromethane, tetrahydrofuran, toluene or pyridine with an acyl halide (R 6 -C(O)-Cl) or acid anhydride (R 6 -C(0)-0-C(0)-R 6 ) in the presence of a base
• Alk (l-4C)alkyl such as N,N-diisopropylethylamine, triethylamine, pyridine or sodium hydride to give 6-N-acylated-l,2,3,4-tetrahydroquinoline derivatives of formula I-a-b.
• acylation of compounds of general formula Vll-a-b to give compounds of general formula I-a-b can also be accomplished by reaction with an appropriate carboxylic acid (R ⁇ CO-zH) in the presence of a coupling reagent such as 0-(benzotriazol-l-yl)- iV;iV;N',N'-tetramethyluronium tetrafluoroborate (TBTU), 0-(7-azabenzotriazol-l-yl)- N ) N,iV r ',N'-tetramemyluronium hexafluorophosphate (HATU) or bromotripyrrolidinophosphonium hexafluorophosphate (PyBrOP) and a tertiary base, e.g. N,N -diisopropylethylamine, in a solvent such as N,N-dime ylformamide or dichloromethane at ambient or elevated temperature.
• demethylation can be accomplished upon reaction of compounds of formula I-c-d with BF 3 Me 2 S complex at ambient temperature.
• the degree of demethylation can be controlled to some extent by carefully controlling the reaction temperature and amount of the demethylating reagent.
• mixtures of mono-, di- and, if relevant, trihydroxy compounds of general formula I-e-i are obtained, which can be separated by chromatography.
• the demethylation reaction generally proceeds with a moderate degree of selectivity, with preferential demethylation at position 5 of the tetrahydroquinoline scaffold.
• the reaction rate for demethylation (dealkylation) of compounds of general formula I-c-d is 5-OMe > 4-(p-OAlk-phenyl) > 7-OMe.
• R 3 is H or a (functionalised) alkoxy group and R 4 and/or R s are (functionalised) alkoxy groups or acyloxy groups
• R 4 and/or R s are (functionalised) alkoxy groups or acyloxy groups
• R 3 is H or a (functionalised) alkoxy group
• R 4 and/or R s are (functionalised) alkoxy groups or acyloxy groups
• R 3 is H or a (functionalised) alkoxy group and R 4 and/or R s are (functionalised) alkoxy groups or acyloxy groups
• the reaction sequence (a) Skraup reaction, (b) acetylation and (c) Friedel-Crafts alkylation of benzene or a substituted benzene as described before leads to the formation of compounds of general formula X-a. It should be noted that the Boc-protective group is cleaved off under the reaction conditions of the Friedel-Crafts reaction.
• N-Boc-l,4-phenylene diamine can be treated with methyl vinyl ketone, followed by acetylation and Friedel-Crafts reaction as described before to give compounds of general formula X-b.
• compounds of general formula X-b can be obtained starting with the partial reduction of 4-methylquinoline (XT) with BH 3 THF complex and sodium bis(2-methoxy-ethoxy)aluminum dihydride to give 4-methyl-l,2- dihydroquinoline, followed by acetylation as described before to give compound XII.
• Reductions of related quinolines to 1,2-dihydroquinolines are described in literature: see, for example: D. Roberts and J. A. Joule, J. Org. Chem. 62:568, 1997; R. F. Heier, L. A. Dolak, J. N. Duncan, D. K. Hyslop, M. F. Lipton, I. J. Martin, M. A.
• Reductive alkylation of the amino group at position 7 of tetrahydroquinoline derivatives of general formula XV-a-b using appropriately substituted aldehydes and a suitable reducing agent e.g. sodium cyanoborohydride or sodium triacetoxy borohydride
• a suitable solvent such as methanol or N,N-dimethylformamide
• the amino group at position 7 of tetrahydroquinoline derivatives of general formula XV-a-b can be acylated with (hetero)aryl carboxylic acids (G- C0 2 H) or acyl chlorides (G-C(0)-C1) as was described previously.
• G- C0 2 H acyl carboxylic acids
• G-C(0)-C1 acyl chlorides
• G aryl, heteroaryl
• the reaction sequence (a) Fmoc-protection to give XIX, (b) reduction of the nitro-group to give XX, followed by (c) regioselective Skraup reaction, (d) acetylation and (e) Fmoc- deprotection as described before leads to the formation of compounds of general formula XXI-a.
• Compounds of general formula XXI-b may be obtained by treating compound XX with methyl vinyl ketone using the conditions described previously for the conversion of compounds of formula II to ⁇ i-b, followed by 1- ⁇ T-acetylation and Fmoc deprotection as described before.
• Subsequent conversion of compounds of general formula XXI to XXIII may be effected by acylation of the 6-amino group using an appropriate acylating agent, for example acyl chloride R 6 -C(0)-C1, followed by Friedel-Crafts reaction with benzene or an appropriate benzene derivative using conditions described previously. Under the Lewis-acidic conditions of the Friedel-Crafts reaction concomitant demethylation of the 7-OMe function in compounds of general formula XXII occurs.
• the thus obtained free 7-OH group in compounds of general formula XXIII may be realkylated or acylated with (functionalised) alkyl halides (e.g.
• Compounds of the present invention in which R and R are connected via a nitrogen atom to the tetrahydroquinoline scaffold can be prepared from compounds of general formula XXIV, wherein PG is a nitrogen protective group, e.g. Boc, acetyl, methylcarbamate or Fmoc, via the previously described reactions e.g.: Skraup reaction or cyclocondensation with methyl vinyl ketone, 1-N-acetylation, cleavage of the protective group, N-alkylation, Friedel-Crafts reaction, nitration, nitro-reduction and acylation (vide supra).
• the requisite compounds of general formula XXXI are accessible from derivatives of general formula XXVIJ using previously described conditions.
• the (regioselective) triflation reaction may be effected under controlled conditions using Tf 2 N-phenyl and N,JV-diisopropylethyl amine in DMF at room temperature. Generally, preferential triflation of the 7-OH group occurs.
• Some of the compounds of the invention which can be in the form of a free base, may be isolated from the reaction mixture in the form of a pharmaceutically acceptable salt.
• the pharmaceutically acceptable salts may also be obtained by treating the free base of formula I with an organic or inorganic acid such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, maleic acid, malonic acid, methanesulphonic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, and ascorbic acid.
• an organic or inorganic acid such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, maleic acid, malonic acid, methanesulphonic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, and ascorbic acid.
• the compounds of the present invention possess at least one chiral carbon atom and may therefore be obtained as pure enantiomers, or as a mixture of enantiomers, or as a mixture of diastereomers.
• Methods for obtaining the pure enantiomers are well known in the art, e.g crystallization of salts which are obtained from optically active acids and the racemic mixture, or chromatography using chiral columns. For diastereomers, straight phase or reversed phase columns may be used.
• the compounds of the invention may form hydrates or solvates. It is known to those of skill in the art that charged compounds form hydrated species when lyophilized with water, or form solvated species when concentrated in a solution with an appropriate organic solvent.
• the compounds of this invention include the hydrates or solvates of the compounds listed.
• EC50 value which must be ⁇ 10 "5 M, preferably ⁇ 10 "7 M.
• EC50 value which must be ⁇ 10 "5 M, preferably ⁇ 10 "7 M.
• a compound with an EC50 which is less than 10 "5 M is generally considered a candidate for drug selection. Preferably this value is lower than 10 "7 M.
• a compound which has a higher EC 5 0, but is selective for the particular receptor may be even a better candidate.
• Methods to determine receptor binding, as well as in vitro and in vivo assays to determine biological activity, of gonadotropins are well known. In general, the expressed receptor is contacted with the compound to be tested and binding or stimulation or inhibition of a functional response is measured.
• isolated DNA encoding the FSH receptor gene is expressed in suitable host cells.
• suitable host cells such a cell might be the Chinese Hamster Ovary cell, but other cells are also suitable.
• the cells are of mammalian origin (Jia et al, MoLEndocrin., 5:759-776, 1991).
• prokaryotic hosts such as bacteria
• eukaryotic hosts such as yeast, plant cells, insect cells, mammalian cells, avian cells and the like.
• Cells expressing the receptor are then contacted with the test compound to observe binding, or stimulation or inhibition of a functional response.
• isolated cell membranes containing the expressed receptor may be used to measure binding of compound.
• radioactively labeled or fluorescently labeled compounds may be used. Also competition binding assays can be performed.
• Another assay involves screening for FSH receptor agonist compounds by determining stimulation of receptor mediated cAMP accumulation.
• a method involves expression of the receptor on the cell surface of a host cell and exposing the cell to the test compound. The amount of cAMP is then measured. The level of cAMP can be reduced or increased, depending on the inhibitory or stimulating effect of the test compound upon binding to the receptor.
• FSH receptor antagonists Screening for FSH receptor antagonists involves incubation of FSH receptor- expressing cells with a concentration range of the test compound in the presence of a fixed, submaximally effective, FSH concentration (i.e., a FSH concentration that induces approximately 80% of the maximal stimulation of cAMP accumulation in the absence of test compound). From the concentration-effect curves, the IC5 0 value and the percentage of inhibition of FSH-induced cAMP accumulation can be determined for each of the test compounds.
• FSH concentration i.e., a FSH concentration that induces approximately 80% of the maximal stimulation of cAMP accumulation in the absence of test compound.
• reporter genes In addition to direct measurement of e.g. cAMP levels in the exposed cell, cells lines can be used which in addition to transfection with receptor encoding DNA are also transfected with a second DNA encoding a reporter gene the expression of which responds to the level of cAMP.
• reporter genes might be cAMP inducible or might be constructed in such a way that they are connected to novel cAMP responsive elements. In general, reporter gene expression might be controlled by any response element reacting to changing levels of cAMP. Suitable reporter genes are e.g. the genes encoding ⁇ -galactosidase, alkaline phosphatase, firefly luciferase and green fluorescence protein.
• the present invention also relates to a pharmaceutical composition
• a pharmaceutical composition comprising a tertrahydroquinoline derivative or pharmaceutically acceptable salts thereof having the general formula I in admixture with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents.
• the auxiliaries must be "acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
• compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, local, or rectal administration, and the like, all in unit dosage forms for administration.
• the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like.
• the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
• sterile liquid carrier e.g. water
• the active agent may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories.
• the active agent can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
• Suitable carriers with which the active agent of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts.
• aqueous suspensions, isotonic saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and or wetting agents, such as propylene glycol or butylene glycol.
• the invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
• the tetrahydroquinoline derivatives of the invention can also be administered in the form of implantable pharmaceutical devices, consisting of a core of active material, encased by a release rate-regulating membrane.
• implantable pharmaceutical devices consisting of a core of active material, encased by a release rate-regulating membrane.
• Such implants are to be applied subcutaneously or locally, and will release the active ingredient at an approximately constant rate over relatively large periods of time, for instance from weeks to years.
• Mettiods for the preparation of implantable pharmaceutical devices as such are known in the art, for example as described in European Patent 0,303,306 (AKZO Nobel N.V.).
• the exact dose and regimen of administration of the active ingredient, or a pharmaceutical composition thereof, will necessarily be dependent upon the therapeutic effect to be achieved (treatment of infertility; contraception), and may vary with the particular compound, the route of administration, and the age and condition of the individual subject to whom the medicament is to be administered.
• a dosage for humans preferably contains 0.0001-25 mg per kg body weight.
• the desired dose may be presented as one dose or as multiple subdoses administered at appropriate intervals throughout the day, or, in case of female recipients, as doses to be administered at appropriate daily intervals throughout the menstrual cycle.
• the dosage as well as the regimen of administration may differ between a female and a male recipient.
• the compounds according to the invention can be used in therapy.
• a further aspect of the invention resides in the use of a tetrahydroquinoline derivative compound having the general formula I for the manufacture of a medicament to be used for the treatment of disorders responsive to FSH receptor mediated pathways.
• a tetrahydroquinoline derivative compound having the general formula I for the manufacture of a medicament to be used for the treatment of disorders responsive to FSH receptor mediated pathways.
• the invention resides in the use of a tetrahydroquinoline derivative compound having the general formula I for the manufacture of a medicament to be used for the control of fertility.
• the invention resides in the use of a tetrahydroquinoline derivative compound having the general formula I for the manufacture of a medicament to be used for the treatment of infertility.
• the invention resides in the use of a tetrahydroquinoline derivative compound having the general formula I for the manufacture of a medicament to be used to prevent fertility.
• the compounds according to the invention can also be used for the treatment of hormone-dependent disorders such as breast cancer, prostate cancer and endometriosis.
• DMA ⁇ JV-dimethylaniline
• DIPEA N ⁇ V-d ⁇ sopropylethylamine
• TFA trifluoroacetic acid
• DtBAD di-tert- butyl azodicarboxylate
• HATU 0-(7-azabenzotriazole-l-yl)-N, ⁇ r ,N',iV r '- tetramethyluronium hexafluorophosphate
• Fmoc 9-fluorenylmethoxycarbonyl
• Fmoc- Cl 9-fluorenylmethoxycarbonylchloride
• DMF N,N-dimethylformamide
• DMAP 4-dimethylaminopyridine
• THF tetrahydrofuran.
• A/B/C 15/80/5 (v/v/v).
• Furan-2-carboxylic acid [l-acetyl-5-hydroxy-7-metfaoxy-4-(4-methoxy-phenyl)-2.2.4- trimethyl- 1.2.3.4-teteahydro-quinolin-6-yl1-amide (a).
• Furan-2-carboxylic acid l-acetyl-5.7-dimethoxy-4-(4-methoxyphenyl)-2.2.4- trimethyl- 1.2.3.4-teteahvdroquinolin-6-yl1-amide
• Biphenyl-4-carboxylic acid 1 -acetyl-5-hydroxy-4-(4-hydroxy-phenyl)-7-methoxy- 2.2.4-trimethyl-1.2.3.4-tettahydro-quinolin-6-yl1-a-mide
• Biphenyl-4-carboxylic acid 1 -acetyl-7-dimethylcarbamoylmethoxy-2.2.4-trimethyl-4- phenyl- 1.2.3.4-tefaahydro-quinolin-6-ylVamide
• Biphenyl-4-carboxylic acid (1 -acetyl-7-carbamoylmethoxy-2.2.4-trimethyl-4-phenyl- 1.2.3.4-teteahvdro-quinolin-6-ylVamide
• Morpholine-4-carboxylic acid (3- ⁇ l-acetyl-6-[(hiphenyl-4-carbonyl)-ammo " [-2.2.4- trimethyl-4-phenyl- 1.2.3.4-tetrahydro-quinolin-7-yloxy -propylVamide
• Furan-2-carboxylic acid (l-acetyl-7-dimemylamino-2.2.4-trimethyl-4-phenyl-1.2.3.4- tetiahydro-quinolin-6-yl)-amide (a). (2.2.4-Trimethyl-1.2-dihydroqumolin-6-yl)-carbamic acid tert-butyl ester
• Fuming nitric acid (3.07 ml) was added dropwise over a period of 10 min to a mixture of the compound described in example 33d (43 g) and acetic acid (230 ml) in CH 2 C1 2 (230 ml).
• the reaction mixture was stirred until full conversion of starting material after which H 2 0 (150 ml) was added.
• the aqueous layer was separated and extracted with CH 2 C1 2 (150 ml).
• the combined organic layers were washed with saturated aq NaHC0 3 (3x200 ml) and brine (200 ml), followed by drying over MgS0 and filtration.
• Methanol (ca 200 ml) was added and the CH 2 C1 2 was carefully removed in vacuo, after which the mixture was allowed to stand at room temperature overnight. The bright yellow crystals were collected by filtration and dried (MgS0 ) in vacuo.
• Furan-2-carboxylic acid (l-acety1-7-dimfithy1am-i ⁇ o-2.2.4-trimethyl-4-phenyl- 1.2.3.4-tetrahvdro-quinolin-6-yl)-amide
• Triethylamine (38 ⁇ l) and 2-furoyl chloride (27 ⁇ l) were added to a solution of the compound described in example 33h (96.6 mg) in CH 2 C1 2 (10 ml) and the resulting mixture was stirred until full conversion of starting material was achieved.
• Biphenyl-4-carboxylic acid (l-acetyl-7-dimethylammo-2.2.4-tiimethyl-4-phenyl- 1.2.3.4-tetrahydro-quinolin-6-yl)-amide
• the compound described in example 33h (96.6 mg) was acylated with 4-biphenylcarboxylic acid (54.4 mg), HATU (157 mg) and DIPEA (239 ⁇ l) in CH 2 C1 2 (10 ml).
• the title compound was purified by preparative HPLC (method B).
• Furan-2-carboxylic acid (1 -acetyl-7-furan-2-ylcarbonylamino-2.2.4-trimethyl-4- phenyl- 1.2.3.4-tetrahvdroquinolin-6-ylVamide
• Biphenyl-4-carboxylic acid (l-acetyl-7-ethylamino-2.2.4-trimethyl-4-phenyl-1.2.3.4- tetrahvdro-quinolin-6-yl)-amide
• Biphenyl-4-carboxylic acid (l-acetyl-7-benzy1a ⁇ ni ⁇ o-2.2.4-trimethyl-4-phenyl- 1.2.3.4- tetiahvdro-quinolin-6-ylVamide
• 5-Bromo-thiophene-2-carboxylic acid (l-acetyl-7-dimethylamino-4-methyl-4-phenyl- 1.2.3.4-tetrahvdro-quinolin-6- yl)-amide
• the compound described in example 48j (74 mg) was acylated 5-bromothiophene-2-carboxylic acid (52 mg), HATU (131 mg) and DIPEA (120 ⁇ l) in CH 2 C1 2 (3 ml).
• the title compound was purified by preparative HPLC and lyophilized.
• the compound described in example 48j (74 mg) was acylated 5-chlorothiophene-2-carboxylic acid (52 mg), HATU (131 mg) and DIPEA (120 ⁇ l) in CH 2 C1 2 (3 ml).
• the title compound was purified by preparative HPLC and lyophilized.
• CHO-FSH in vitro bioactivity FSH activity of compounds were tested in Chinese Hamster Ovary (CHO) cells stably transfected with the human FSH receptor and cotransfected with a cAMP responsive element (CRE) / promotor directing the expression of a firefly luciferase reporter gene. Binding of ligand to the Gs-coupled FSH receptor will result in an increase of cAMP, which in turn will induce an increased transactivation of the luciferase reporter construct.
• CRE cAMP responsive element
• the luciferase signal was quantified using a luminescence counter.
• EC50 values concentration of test compound causing half-maximal (50 %) stimulation or reduction
• the software program GraphPad PRISM, version 3.0 (GraphPad software Inc., San Diego) was used.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Diabetes (AREA)
• Gynecology & Obstetrics (AREA)
• Pregnancy & Childbirth (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Quinoline Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)

Priority Applications (2)

Applications Claiming Priority (6)

Publications (2)

Family

ID=39311811

Family Applications (1)

Country Status (18)

Families Citing this family (15)

Family Cites Families (10)

• 2003
  • 2003-12-15 TW TW092135447A patent/TWI306855B/zh not_active IP Right Cessation
  • 2003-12-16 US US10/540,336 patent/US7858794B2/en not_active Expired - Lifetime
  • 2003-12-16 UA UAA200505288A patent/UA81442C2/xx unknown
  • 2003-12-16 WO PCT/EP2003/051025 patent/WO2004056780A2/en not_active Ceased
  • 2003-12-16 RU RU2005122946/04A patent/RU2328488C2/ru not_active IP Right Cessation
  • 2003-12-16 CA CA2508952A patent/CA2508952C/en not_active Expired - Lifetime
  • 2003-12-16 AU AU2003298363A patent/AU2003298363B2/en not_active Ceased
  • 2003-12-16 AT AT03796105T patent/ATE423771T1/de not_active IP Right Cessation
  • 2003-12-16 ES ES03796105T patent/ES2321830T3/es not_active Expired - Lifetime
  • 2003-12-16 BR BR0317518-9A patent/BR0317518A/pt active Search and Examination
  • 2003-12-16 EP EP03796105A patent/EP1578726B1/de not_active Expired - Lifetime
  • 2003-12-16 RS YUP-2005/0457A patent/RS51293B/sr unknown
  • 2003-12-16 NZ NZ540578A patent/NZ540578A/en not_active IP Right Cessation
  • 2003-12-16 PL PL377318A patent/PL377318A1/pl not_active Application Discontinuation
  • 2003-12-16 JP JP2004561499A patent/JP4545001B2/ja not_active Expired - Fee Related
  • 2003-12-18 CL CL200302685A patent/CL2003002685A1/es unknown
  • 2003-12-19 AR ARP030104729A patent/AR042630A1/es unknown
• 2004
  • 2004-01-05 PE PE2004000023A patent/PE20040928A1/es not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events